1206640-82-5

Basic information

• Product Name: 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-(difluoroMethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-y;1-(difluoromethyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-(Difluoromethyl)pyrazole-4-boronic acid pinacol ester;(1-(DIFLUOROMETHYL)-1H-PYRAZOL-4-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1206640-82-5
• Molecular Formula: C₁₀H₁₅BF₂N₂O₂
• Molecular Weight: 244.0461064
• Mol File: 1206640-82-5.mol

Chemical Properties

• Boiling Point: 294.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.01±0.19(Predicted)
• CAS DataBase Reference: 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1206640-82-5)
• EPA Substance Registry System: 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1206640-82-5)

Safety Data

• Hazardous Substances Data: 1206640-82-5(Hazardous Substances Data)

Usage

Uses

Used in Synthetic Organic Chemistry:
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a synthetic intermediate for the preparation of various complex organic molecules. Its unique structure, which includes a 1H-pyrazole ring and a 1,3,2-dioxaborolan-2-yl unit, makes it a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Fluorination Strategies:
Due to the presence of a difluoromethyl group, 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a fluorination agent in the synthesis of fluorinated compounds. Fluorination is an important strategy in organic chemistry, as the introduction of fluorine atoms can significantly alter the physical, chemical, and biological properties of molecules, making them valuable in various applications, such as drug development and materials science.

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 
• 956477-67-1 4-bromo-1-(difluoromethyl)-1H-pyrazole 
• 73183-34-3 bis(pinacol)diborane 
• 1895-39-2 sodium chlorodifluoroacetate 
• 75-45-6 Chlorodifluoromethane 

Downstream Products

• 1238697-10-3 1-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-2-fluorophenyl}-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Pyridazinol compound and derivatives, preparation method, weeding compositions and application thereof

The invention belongs to the technical field of pesticides, and particularly relates to a pyridazinol compound and derivatives, a preparation method, weeding compositions and application thereof. Thepyridazinol compound is shown as a general formula I whi

PYRAZOLOTRIAZINES

The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

Amide compounds and uses thereof

Provided herein are novel amide compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the definition of each symbol is as described in the description.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Fused tricyclic compounds and application thereof in medicaments

The invention relates to fused tricyclic compounds and an application thereof in medicaments, and in particular to an application of the fused tricyclic compounds in medicaments for treating and/or preventing hepatitis B. In particular, the invention rela

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.